TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06365606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStatis Syphilis Ab Test
Description: Capillary (fingerstick) blood, venous whole blood and plasma samples prospectively collected from the participants will be tested on the iStatis Syphilis Ab Test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStatis Syphilis Ab Test
Description: Capillary (fingerstick) blood, venous whole blood and plasma samples prospectively collected from the participants will be tested on the iStatis Syphilis Ab Test.
Study: NCT06458829

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SEARCH-AF
Description: SEARCH-AF program will include opportunistic screening among old adults during primary care visits and promoting strategies. Promoting strategies will be developed based on the Consolidated Framework for Implementation Research framework which may include leadership engagement, policy support, providing screening resources, atrial fibrillation screening and management training. General practitioner or nurse in each health care center will implement point-on-care screening. The intervention will last for six months and followed up for another six months.
Study: NCT05502588

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Forest Bathing
Description: Participants will participate in two, 60-90 minute self-guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails and be given prompts to consciously use their five senses in the forest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Forest Bathing
Description: Participants will participate in two, 60-90 minute guided forest bathing sessions over the course of a year in one of four Vancouver, B.C. park trails. They will be invited by a certified forest therapy guide to consciously use their five senses in the forest.
Study: NCT06458829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEARCH-AF
Description: SEARCH-AF program will include opportunistic screening among old adults during primary care visits and promoting strategies. Promoting strategies will be developed based on the Consolidated Framework for Implementation Research framework which may include leadership engagement, policy support, providing screening resources, atrial fibrillation screening and management training. General practitioner or nurse in each health care center will implement point-on-care screening. The intervention will last for six months and followed up for another six months.
Study: NCT06090474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDC-002
Description: Combination of NDC-002B and NDC-002C
Study: NCT04902287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Intervention for the Engagement of Families (TIES)
Description: This intervention involves training service personnel in a method of communication that elicits a person's intrinsic motivation for change.
Study: NCT06125535

Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-phenotyping by biomarkers concentration
Description: Plasma will be collected at ICU admission (i.e., \< 6 hours from graft reperfusion), centrifuged (1500G for 15 min), frozen at -80°c, and then centralized at the Institutional laboratory. The following biomarkers will be assessed: sRAGE, SP-D, P-selectin (for alveolar damage); ICAM-1, IL6, IL8, IL10, TNF-alfa, IFN-gamma, CCL2, GM-CSF, TNFR1 (inflammation); angiopoietin-1, angiopoietin-2, TIMP-1 (endothelial damage). Analyses will be carried out on a Luminex platform (BioRad, Hercules, California, USA) - available at our Institution.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sub-phenotyping by biomarkers concentration
Description: Plasma will be collected at ICU admission (i.e., \< 6 hours from graft reperfusion), centrifuged (1500G for 15 min), frozen at -80°c, and then centralized at the Institutional laboratory. The following biomarkers will be assessed: sRAGE, SP-D, P-selectin (for alveolar damage); ICAM-1, IL6, IL8, IL10, TNF-alfa, IFN-gamma, CCL2, GM-CSF, TNFR1 (inflammation); angiopoietin-1, angiopoietin-2, TIMP-1 (endothelial damage). Analyses will be carried out on a Luminex platform (BioRad, Hercules, California, USA) - available at our Institution.
Study: NCT06418542

Intervention type: DEVICE
Group type: OTHER
Intervention: use of florescein
Description: Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.

Intervention type: DEVICE
Group type: OTHER
Intervention: use of florescein
Description: Fluorescein, an organic contrast agent, is used in FFA to detect retinal pathologies.
Study: NCT04628507

Intervention type: OTHER
Intervention: Spent media collection
Description: Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
Study: NCT06653621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Subjects receive liposomal bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block mode : adductor block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block mode : adductor block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for adductor block under ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Subjects receive bupivacaine as a regional anesthetic for femoral triangle block or adductor block under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block mode: femoral triangle block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block mode: femoral triangle block
Description: Subjects receive liposomal bupivacaine or bupivacaine as a regional anesthetic for femoral triangle block under ultrasound guidance.
Study: NCT06653166

Intervention type: DEVICE
Intervention: bougie (S Guide)
Description: bougie (S Guide)

Intervention type: DEVICE
Intervention: bougie (S Guide)
Description: bougie (S Guide)

Intervention type: DEVICE
Intervention: videolaryngoscopy
Description: videolaryngoscopy hyperangulated or Macintosh

Intervention type: DEVICE
Intervention: videolaryngoscopy
Description: videolaryngoscopy hyperangulated or Macintosh
Study: NCT05269355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unesbulin
Description: Unesbulin will be administered as per the dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dacarbazine
Description: Dacarbazine will be administered as per the dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine will be administered as per the dose and schedule specified in the arm description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the schedule specified in the arm description.
Study: NCT04644718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: tDCS will be administered using a battery driven stimulator along with intensive SLT. The anode electrode (5-7cm2) will be placed over the left M1 while the cathode will be positioned over the controlateral supraorbital area in both groups ((Lindenberg et al., 2013; Meinzer et al., 2016; Stahl et al., 2019), (based on the 10-20 EEG system) (Darkow et al., 2017). Stimulation will be provided via an electrode using a Soterix device (Soterix Medical Inc., New York, NY). During sham tDCS (control group), the current will be ramped up and remained for 30 s at (2 mA) before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp (Gandiga et al., 2006). Both groups will receive a total of 30 consecutive stimulation sessions over six weeks.
Study: NCT05243771

Intervention type: PROCEDURE
Intervention: Rectal resection with diverting stoma
Description: Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created

Intervention type: PROCEDURE
Intervention: Rectal resection without diverting stoma
Description: Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created

Intervention type: PROCEDURE
Intervention: Rectal resection with permanent colostomy
Description: Patients in this group will receive a rectal resection and a permanent colostomy will be created
Study: NCT06170645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APA program
Description: An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: APA program
Description: An APA program of 12 weeks, 2 sessions of 1h/week for mixed endurance, strengthening and stretching work. The program can be realized at home or in structure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transcutaneous VNS
Description: After each APA session, a 1h-tVNS session is delivered on the conchae aurea of the left ear, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous VNS
Description: After each APA session, a 1h-tVNS session is delivered on the left earlobe, in resting condition. Parameters of tVNS : frequency 20Hz, impulsion 200ms, amplitude 1mA below the unpleasant sensation level.
Study: NCT06011486

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lymphocyte infusion (ImmuneCellVir-I)
Description: Infusion of donor CMV specific cells into patients eligible to the trial
Study: NCT05559814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraluminal peppermint oil
Description: Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraluminal flushing of placebo solution through the scope during scope withdrawal
Study: NCT05835401

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice rich in nitrate
Description: The participant will intake beetroot juice rich in NO3 (800mg). Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice depleted in nitrate
Description: The participant will intake beetroot juice depleted in NO3. Two hours after intake the last bottle of juice, the participants will go to the laboratory for the handgrip and cardiovascular tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
Study: NCT04854655

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resin composite
Description: nanofilled resin composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activa Presto
Description: calcium and phosphate hybrid material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giomer
Description: fluoride releasing hybrid material
Study: NCT06596304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity-resistance training with lower limb blood flow restriction
Description: In the LIRT-BFR, participants will perform 4 sets of 20 bilateral leg presses and knee extensions repetitions with BFR at 30% of 1-RM, with 30-second rest intervals between sets, in an estimated total of 30-minute session per participant. Cuffs will be placed in the upper thighs and inflated with a pressure that is 1.3 times the individual's ankle systolic blood pressure in the data collection day for the entirety of the training session with a commercial cuff (width×length; 11×85 cm, SC10™, Hokanson, Inc., WA, USA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Resistance Training
Description: In the HIRT participants will perform bilateral leg presses and knee extension without BFR at 75% of one-repetition maximum (1-RM), for 3 sets of 10 reps, with 2-minute rest intervals, in an estimated total of 30-minute session per participant.
Study: NCT06657079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days
Description: combined standard aerosolized doses of budesonide (0.5 mg/2 mL) every 12 hours and ipratropium bromide (500/2 mL) every eight hours for up to five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline inhaler
Study: NCT06656416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-100
Description: ALTO-100 40 mg tablet BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID
Study: NCT06656559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab and Surufatinib
Description: Envafolimab: 150mg, SC, qw Surufatinib: 150mg, p.o., qd
Study: NCT06657417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Description: Standard video laryngoscopy before video laryngoscopy with additional larynGuide overlay

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video larnygoscopy
Description: Video laryngoscopy with additional larynGuide overlay before standard video laryngoscopy
Study: NCT06656130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pranayama
Description: Pranayama is the practice of breath regulation. It's a main component of yoga, an exercise for physical and mental wellness. The practice of pranayama involves breathing exercises and patterns. Patient purposely inhale, exhale, and hold his/her breath in a specific sequence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jacobson's progressive muscle relaxation technique
Description: Jacobson's relaxation technique is a type of therapy that focuses on tightening and relaxing specific 14 muscle groups in sequence. It's also known as progressive relaxation therapy. By concentrating on specific areas and tensing and then relaxing them, patient can become more aware of his/her body and physical sensations,
Study: NCT06656026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 granules
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 granules
Description: Oral
Study: NCT06657664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy with sterile saline at 2.5ºC
Description: the root canals are given a final irrigation with 20 mL cold (2.5oC) saline solution for 5 minutes before obturation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intaoral cryotherapy
Description: ice sticks (wrapped in sterile gauze if needed) using plastic pipette droppers filled with freezed sterile water are placed intraorally in the mouth on the apices of the treated tooth on both buccal and palatal sides for 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Both intracanal and intraoral cryotherapy
Description: Canal is irrigated with iced saline for 5 minutes before obturation . Root canal is obturated and coronal restoration is done. Then, application of intraoral cryotherapy is performed by ice sticks for 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: laser irradiation on the soft tissues covering the apices of the tooth on both buccal and palatal surfaces respectively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: , all occlusal contacts were reduced by 1 mm
Study: NCT05987280

Intervention type: OTHER
Intervention: eDelphi method
Description: eDelphi method

Intervention type: OTHER
Intervention: eDelphi method
Description: eDelphi method
Study: NCT05105633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (which may include intravenous Alteplase)
Description: Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
Study: NCT05663788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-learning module
Description: The intervention is a structured e-learning module on a web-based platform (www.trainingopticaldiagnosis.com) that consists of:~* 10 modules, including theoretical knowledge and multiple exercises.~* 2 seminars with a tutor (after Module 5 and Module 10)~* feedback from the tutor on three cases recorded by the participant.~* 20-images test before and after the content described above (10 Modules, 2 seminars with tutors and feedback on three cases)~All the Gastroenterologists participating in the study will predict deep submucosal invasion in their routine colonoscopies and will register clinical outcomes during 12 months. The randomisation and intervention will be conducted 6 months after starting to predict deep submucosal invasion and registering clinical outcomes.
Study: NCT05842707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dualCAR-NK19/70 cell
Description: Given by IV (vein)
Study: NCT05125939

Intervention type: OTHER
Intervention: Comparison of ADR
Description: The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.

Intervention type: OTHER
Intervention: Comparison of ADR
Description: The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.

Intervention type: OTHER
Intervention: Comparison of ADR
Description: The investigators will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.
Study: NCT06657261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The patient group receiving deep and superficial serratus anterior plane block
Description: The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The patient group receiving a combination of deep serratus anterior plane block and transverse thoracic muscle plane block
Description: The ultrasound device to be used , the type of single-use ultrasound-compatible block needle, the type of local anesthetic agent to be administered to the patient, the concentration of the local anesthetic agent, and the total dose of the local anesthetic agent to be administered to the patient will be the same.
Study: NCT04971590

Intervention type: OTHER
Intervention: Participant completed survey
Description: Participants will be required to complete the participant survey.

Intervention type: OTHER
Intervention: Medical chart review
Description: Data will be collected from medical charts of participants.
Study: NCT04661813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXTRA-CVD Virtual Care
Description: The original EXTRA-CVD intervention was developed to improve blood pressure and cholesterol control among People Living with HIV. The intervention will be adapted to the post-COVID healthcare delivery landscape as a virtual intervention delivered by phone, teleconference, internet support groups, and nurse care coordination.
Study: NCT06448988

Intervention type: OTHER
Intervention: Park Bench position
Description: To evaluate, during the procedure, the variation in regional distribution of intrapulmonary volume in the dependent and non-dependent lung regions in patients undergoing neurosurgical intervention between supine and Park-Bench position.
Study: NCT06315010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid.